Abstract
Molecular imaging studies have generated important in vivo insights into the etiology of schizophrenia and treatment response. This article first reviews the PET and SPECT evidence implicating dopaminergic dysfunction, especially presynaptic dysregulation, as a mechanism for psychosis. Second, it summarises the neurochemical imaging studies of antipsychotic action, focussing on D2/3 receptors. These studies show that all currently licensed antipsychotic drugs block striatal D2/3 receptors in vivo- a site downstream of the likely principal dopaminergic pathophysiology in schizophrenia- and that D2/3 occupancy above a threshold is required for antipsychotic treatment response. However, adverse events, such as extra-pyramidal side-effects or hyperprolactinemia, become much more likely at higher occupancy levels, which indicates there is an optimal ‘therapeutic window‘ for D2/3 occupancy, and questions the use of high doses of antipsychotic treatment in clinical practice and trials. Adequate D2/3 blockade by antipsychotic drugs is necessary but not always sufficient for antipsychotic response. Molecular imaging studies of clozapine, the one antipsychotic licensed for treatment resistant schizophrenia, have provided insights into the mechanisms underlying its unique efficacy. To link this pharmacology to the phenomenology of the illness, we discuss the role of dopamine in motivational salience and show how i) psychosis could be viewed as a process of aberrant salience, and ii) antipsychotics might provide symptomatic relief by blocking this aberrant salience. Finally, we discuss the implications of these PET and SPECT findings for new avenues of drug development.
Keywords: Schizophrenia, psychosis, mechanisms, treatment, antipsychotic, imaging, etiology, PET
Current Pharmaceutical Design
Title: Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging
Volume: 15 Issue: 22
Author(s): O. D. Howes, A. Egerton, V. Allan, P. McGuire, P. Stokes and S. Kapur
Affiliation:
Keywords: Schizophrenia, psychosis, mechanisms, treatment, antipsychotic, imaging, etiology, PET
Abstract: Molecular imaging studies have generated important in vivo insights into the etiology of schizophrenia and treatment response. This article first reviews the PET and SPECT evidence implicating dopaminergic dysfunction, especially presynaptic dysregulation, as a mechanism for psychosis. Second, it summarises the neurochemical imaging studies of antipsychotic action, focussing on D2/3 receptors. These studies show that all currently licensed antipsychotic drugs block striatal D2/3 receptors in vivo- a site downstream of the likely principal dopaminergic pathophysiology in schizophrenia- and that D2/3 occupancy above a threshold is required for antipsychotic treatment response. However, adverse events, such as extra-pyramidal side-effects or hyperprolactinemia, become much more likely at higher occupancy levels, which indicates there is an optimal ‘therapeutic window‘ for D2/3 occupancy, and questions the use of high doses of antipsychotic treatment in clinical practice and trials. Adequate D2/3 blockade by antipsychotic drugs is necessary but not always sufficient for antipsychotic response. Molecular imaging studies of clozapine, the one antipsychotic licensed for treatment resistant schizophrenia, have provided insights into the mechanisms underlying its unique efficacy. To link this pharmacology to the phenomenology of the illness, we discuss the role of dopamine in motivational salience and show how i) psychosis could be viewed as a process of aberrant salience, and ii) antipsychotics might provide symptomatic relief by blocking this aberrant salience. Finally, we discuss the implications of these PET and SPECT findings for new avenues of drug development.
Export Options
About this article
Cite this article as:
Howes D. O., Egerton A., Allan V., McGuire P., Stokes P. and Kapur S., Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging, Current Pharmaceutical Design 2009; 15 (22) . https://dx.doi.org/10.2174/138161209788957528
DOI https://dx.doi.org/10.2174/138161209788957528 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combining Feature Extraction Methods to Assist the Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design The Genomic Approaches to Major Depression
Current Pharmacogenomics Therapeutic Targets for the Treatment of Comorbidities Associated with Epilepsy
Current Molecular Pharmacology Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Treatment and Outcome of Pulmonary Arterial Hypertension in HIVInfected Patients: A Review of the Literature
Current HIV Research ON-OFF Interactions in the Retina: Role of Glycine and GABA
Current Neuropharmacology Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography
Current Radiopharmaceuticals Polycations Selectively Blocking Tissue Factor-Dependent FVII Activation: Collective In Vitro Anticoagulation Studies§
Inflammation & Allergy - Drug Targets (Discontinued) Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Editorial (Thematic Issue:“Prion; Mechanism and Function”)
Current Pharmaceutical Biotechnology The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Glaucoma: In Search of Better Neurotherapeutics
Current Neuropharmacology Can MDMA Play a Role in the Treatment of Substance Abuse?
Current Drug Abuse Reviews Drug Trials in Dementia: Challenging Ethical Dilemmas
Current Alzheimer Research Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology Structure-Based Approaches to the Development of Novel Anti-Malarials
Current Drug Targets Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy
Current Topics in Medicinal Chemistry